- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting BTK in CLL: Beyond Ibrutinib
Authors
Keywords
-
Journal
Current Hematologic Malignancy Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-04-27
DOI
10.1007/s11899-019-00512-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Non-covalent inhibition of C481S Bruton’s tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib resistant CLL
- (2018) Sean D. Reiff et al. BLOOD
- CEP: a new β2integrin ligand in inflamed tissue
- (2018) Markus Sperandio BLOOD
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- HSP90 inhibition without heat shock response
- (2018) John C. Byrd BLOOD
- Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation to GPVI
- (2018) Phillip L.R. Nicolson et al. HAEMATOLOGICA
- Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
- (2018) James J. Crawford et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System
- (2018) Connie Cheng et al. LEUKEMIA & LYMPHOMA
- First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
- (2018) John C. Byrd et al. Oncotarget
- Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation to GPVI
- (2018) Phillip L.R. Nicolson et al. HAEMATOLOGICA
- LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors
- (2018) Barbara Brandhuber et al. Clinical Lymphoma Myeloma & Leukemia
- Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies
- (2018) Avirup Guha et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
- (2018) Sean D. Reiff et al. Cancer Discovery
- Ibrutinib and Aspergillus: a Btk-targeted risk
- (2018) Jennifer A. Woyach BLOOD
- Macrophage TNF-α licenses donor T cells in murine bone marrow failure and can be implicated in human aplastic anemia
- (2018) Wanling Sun et al. BLOOD
- Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
- (2018) Jennifer R. Brown et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation
- (2018) Rashmi Kanagal-Shamanna et al. CANCER
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia
- (2017) Alexander Beyer et al. JOURNAL OF EMERGENCY MEDICINE
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
- (2017) Tjeerd Barf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
- (2017) Dan A. Landau et al. Nature Communications
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
- (2016) Adam R. Johnson et al. ACS Chemical Biology
- Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia
- (2016) L. Falchi et al. ANNALS OF ONCOLOGY
- Setdb1 maintains hematopoietic stem and progenitor cells by restricting the ectopic activation of nonhematopoietic genes
- (2016) S. Koide et al. BLOOD
- The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
- (2016) Darryl P. Leong et al. BLOOD
- The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
- (2016) Sarah E.M. Herman et al. CLINICAL CANCER RESEARCH
- Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
- (2016) J. R. Brown et al. HAEMATOLOGICA
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
- (2016) Jan A. Burger et al. Nature Communications
- Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
- (2016) J. R. Brown et al. HAEMATOLOGICA
- A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
- (2015) H. S. Walter et al. BLOOD
- Hypermorphic mutation of phospholipase C, 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
- (2015) T.-M. Liu et al. BLOOD
- Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor
- (2015) Na Li et al. CANCER RESEARCH
- Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
- (2015) S. E. M. Herman et al. CLINICAL CANCER RESEARCH
- Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation
- (2015) Minke E. Binnerts et al. MOLECULAR CANCER THERAPEUTICS
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
- (2014) J. A. Woyach et al. BLOOD
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
- (2013) J. A. Woyach et al. BLOOD
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia
- (2010) Tait D. Shanafelt et al. CANCER
- Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
- (2008) M. Muzio et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- (2008) Apostolia-Maria Tsimberidou et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started